Acorn Capital Advisors, LLC 13F holdings
Acorn Capital Advisors, LLC reported 20 positions with a total reported value of $366.5M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: CGON CG ONCOLOGY INC (21.9%), URGN UROGEN PHARMA LTD (16.8%), TRVI TREVI THERAPEUTICS INC (10.9%), CADL CANDEL THERAPEUTICS INC (9.8%), PBYI PUMA BIOTECHNOLOGY INC (9.1%). Against 2026-03-31 it opened 1 new position and exited 3. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Acorn Capital Advisors, LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
20 largest of 20 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| CGON CG ONCOLOGY INC | 1,131,500 | $80.4M | 21.9% |
| URGN UROGEN PHARMA LTD | 1,673,420 | $61.6M | 16.8% |
| TRVI TREVI THERAPEUTICS INC | 2,144,844 | $40.0M | 10.9% |
| CADL CANDEL THERAPEUTICS INC | 3,497,948 | $36.0M | 9.8% |
| PBYI PUMA BIOTECHNOLOGY INC | 4,131,299 | $33.5M | 9.1% |
| JBIO JADE BIOSCEINCES INC | 986,760 | $21.9M | 6.0% |
| BCAX BICARA THERAPEUTICS | 643,381 | $19.1M | 5.2% |
| KPTI KARYOPHARM THERAPEUTICS INC | 1,518,113 | $14.8M | 4.0% |
| OKUR ONKURE THERAPEUTICS INC | 2,839,674 | $12.9M | 3.5% |
| HELUS PHARMA INC. | 1,540,266 | $10.2M | 2.8% |
| TARA PROTARA THERAPEUTICS INC | 1,752,115 | $6.7M | 1.8% |
| AURA AURA BIOSCIENCES INC | 929,077 | $6.6M | 1.8% |
| LONA LEONABIO, INC. | 634,539 | $5.8M | 1.6% |
| VSTM VERASTEM INC | 1,469,153 | $5.6M | 1.5% |
| WHWK WHITEHAWK THERAPEUTICS INC | 1,139,363 | $5.2M | 1.4% |
| QTTB Q32 BIO INC. | 216,171 | $2.8M | 0.8% |
| ENGN EUGENE THERAPEUTICS | 1,271,257 | $2.2M | 0.6% |
| JSPR JASPER THERAPEUTICS | 1,438,159 | $604.0K | 0.2% |
| BCAB BIOATLA INC | 108,126 | $447.6K | 0.1% |
| VYNE THERAPEUTICS INC | 1,425 | $926 | <0.1% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 1 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| ENGN EUGENE THERAPEUTICS | 1,271,257 | $2.2M | 0.6% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 3 in all · reported value as of 2026-03-31
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| KPTI KARYOPHARM THERAPEUTICS INC | 287,826 | 1,518,113 | +427.4% | $14.8M |
| JBIO JADE BIOSCEINCES INC | 786,760 | 986,760 | +25.4% | $21.9M |
| AURA AURA BIOSCIENCES INC | 595,744 | 929,077 | +56.0% | $6.6M |
| CGON CG ONCOLOGY INC | 1,130,501 | 1,131,500 | +0.1% | $80.4M |
| JSPR JASPER THERAPEUTICS | 1,411,492 | 1,438,159 | +1.9% | $604.0K |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| BCAB BIOATLA INC | 5,406,345 | 108,126 | -98.0% | $447.6K |
| QTTB Q32 BIO INC. | 315,052 | 216,171 | -31.4% | $2.8M |
| BCAX BICARA THERAPEUTICS | 643,382 | 643,381 | -0.0% | $19.1M |
CIK 2054410 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
